Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Orthofix MedicalOFIX -1.53%58 3-Year Revenue Growth Rate is -3.30% as of Jun. 2026. GuruFocus rates OFIX with a GF Score™ of 58/100 and a GF Value™ of $13.93 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 754 Medical Devices & Instruments companies, Orthofix Medical ranks worse than 65.78% on this metric.
During the past 12 months, Orthofix Medical's average Revenue per Share Growth Rate was -0.40% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -3.30% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -1.50% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -0.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Orthofix Medical was 28.70% per year. The lowest was -10.50% per year. And the median was 7.15% per year.
Orthofix Medical (NAS:OFIX) 3-Year Revenue Growth Rate Explanation
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.
Orthofix Medical 3-Year Revenue Growth Rate Related Terms
OFIX vs VMD, VREX, KIDS: 3-Year Revenue Growth Rate Comparison
For the Medical Devices subindustry, Orthofix Medical's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orthofix Medical 3-Year Revenue Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Orthofix Medical's 3-Year Revenue Growth Rate distribution charts can be found below:
* The bar in red indicates where Orthofix Medical's 3-Year Revenue Growth Rate falls into.
Orthofix Medical 3-Year Revenue Growth Rate Calculation
This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.
What does a 3-Year Revenue Growth Rate of -3.30% mean?
Orthofix Medical (OFIX) has a 3-Year Revenue Growth Rate of -3.30% as of Jun. 2026. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Orthofix Medical and its competitors. According to the industry distribution chart, Orthofix Medical ranks #496 out of 754 companies in the Medical Devices & Instruments industry, placing it in the top 65.8%.
Is Orthofix Medical's 3-Year Revenue Growth Rate too high?
Orthofix Medical's current 3-Year Revenue Growth Rate is -3.30%. Based on the distribution chart, Orthofix Medical ranks #496 out of 754 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Orthofix Medical has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Orthofix Medical's 3-Year Revenue Growth Rate compare to VMD and VREX?
According to the Medical Devices & Instruments industry distribution chart, Orthofix Medical ranks #496 out of 754 companies for 3-Year Revenue Growth Rate. This places Orthofix Medical in the lower half of its industry. The industry median 3-Year Revenue Growth Rate is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year Revenue Growth Rate for a Medical Devices & Instruments company?
The median 3-Year Revenue Growth Rate among Medical Devices & Instruments companies is 3.70, based on 754 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year Revenue Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year Revenue Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year Revenue Growth Rate mean?
A high 3-Year Revenue Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year Revenue Growth Rate is the 3-year average growth rate of Revenue per share. View historical data for Orthofix Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year Revenue Growth Rate is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orthofix Medical's current 3-Year Revenue Growth Rate is -3.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orthofix Medical stock overvalued right now?
Based on GuruFocus' analysis, Orthofix Medical (OFIX) is currently considered Possible Value Trap. The stock's GF Value™ is $13.93, compared to a current price of $9.64 — trading 30.8% below its estimated fair value. The current 3-Year Revenue Growth Rate is -3.30%. Orthofix Medical's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year Revenue Growth Rate calculated?
3-Year Revenue Growth Rate is calculated from a company's financial statements. For Orthofix Medical (OFIX), the current 3-Year Revenue Growth Rate is -3.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orthofix Medical (OFIX) Overvalued in 2026?
Based on GuruFocus' analysis, Orthofix Medical stock appears to be undervalued.
The current stock price of $9.64 is trading 30.8% below its estimated GF Value™ of $13.93.
GuruFocus considers Orthofix Medical to be Possible Value Trap.
Key valuation signals for OFIX:
3-Year Revenue Growth Rate: -3.30%
GF Value™: $13.93 vs. price of $9.64 (30.8% below fair value)
No single metric tells the full story. See the OFIX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two reportable segments: Global Spine and Global Limb Reconstruction. The Global Spine segment offers bone growth therapies, spinal implants, biologics, and enabling technologies used in spinal procedures. The Global Limb Reconstruction segment provides products and solutions for limb deformity correction, limb lengthening, fracture management, and limb preservation, supported by digital technologies. It generates the majority of its revenue from the Global Spine segment.
58GF Score
Get the complete analysis for OFIX
3-Year Revenue Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OFIX has been successfully added to your 
